DK0857718T3 - Endothelinantagonist - Google Patents

Endothelinantagonist

Info

Publication number
DK0857718T3
DK0857718T3 DK97925279T DK97925279T DK0857718T3 DK 0857718 T3 DK0857718 T3 DK 0857718T3 DK 97925279 T DK97925279 T DK 97925279T DK 97925279 T DK97925279 T DK 97925279T DK 0857718 T3 DK0857718 T3 DK 0857718T3
Authority
DK
Denmark
Prior art keywords
endothelin antagonist
alpha
chain
carbon atoms
active ingredient
Prior art date
Application number
DK97925279T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK0857718T3 publication Critical patent/DK0857718T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S502/00—Catalyst, solid sorbent, or support therefor: product or process of making
    • Y10S502/50—Stabilized
    • Y10S502/503—Crush strength

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK97925279T 1996-06-10 1997-06-04 Endothelinantagonist DK0857718T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14716696 1996-06-10
JP1019197 1997-01-23
PCT/JP1997/001892 WO1997047595A1 (fr) 1996-06-10 1997-06-04 Antagoniste de l'endotheline

Publications (1)

Publication Number Publication Date
DK0857718T3 true DK0857718T3 (da) 2002-12-16

Family

ID=26345421

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97925279T DK0857718T3 (da) 1996-06-10 1997-06-04 Endothelinantagonist

Country Status (14)

Country Link
US (2) US6242485B1 (fr)
EP (1) EP0857718B1 (fr)
JP (1) JP3187438B2 (fr)
KR (1) KR19990036322A (fr)
CN (3) CN102126998B (fr)
AT (1) ATE222237T1 (fr)
CA (1) CA2229183C (fr)
DE (1) DE69714698T2 (fr)
DK (1) DK0857718T3 (fr)
ES (1) ES2182088T3 (fr)
NO (1) NO980553L (fr)
PT (1) PT857718E (fr)
TW (1) TW418188B (fr)
WO (1) WO1997047595A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811774A (pt) * 1997-09-09 2000-08-29 Procter & Gamble Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
SK3382000A3 (en) * 1997-09-09 2000-10-09 Procter & Gamble A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders
HUP0004436A3 (en) * 1997-09-09 2001-09-28 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
EP0978284B1 (fr) 1997-11-28 2008-07-23 Sucampo AG Utilisation de composés de type 15-keto-prostaglandine-e en tant qu'antagoniste de l'endotheline
CA2364948C (fr) 1999-03-05 2011-04-26 Duke University Analogues de prostaglandines c16 fp selectives insaturees
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) * 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
WO2003020283A2 (fr) * 2001-08-29 2003-03-13 Novartis Ag Procede pour traiter une retinopathie diabetique
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
CA2490409A1 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
EP1562604B1 (fr) * 2002-10-23 2012-01-04 Sucampo AG Composes de prostaglandine pour traiter l'obesite
AU2003292556B2 (en) 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
KR20120005052A (ko) 2003-08-21 2012-01-13 수캄포 아게 안과용 조성물
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
AU2006209072B2 (en) 2005-01-27 2011-02-24 Sucampo Ag Method and composition for treating central nervous system disorders
US8143316B2 (en) 2005-03-04 2012-03-27 Sucampo Ag Method for treating peripheral vascular diseases
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2414904C2 (ru) * 2005-03-31 2011-03-27 Асахи Гласс Компани, Лимитед ЗАЩИТНОЕ СРЕДСТВО ДЛЯ НЕЙРОНА СЕТЧАТКИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО КОМПОНЕНТА ПРОИЗВОДНОЕ ПРОСТАГЛАНДИНА F2α
EP1871380B1 (fr) * 2005-04-12 2011-10-19 Sucampo AG Utilisation combinee d'un compose de prostaglandine et d'un inhibiteur de pompe a protons pour le traitement des troubles gastro-intestinaux
RU2420291C3 (ru) * 2006-01-24 2020-07-21 Р-Тек Уено, Лтд. Состав в мягкой желатиновой капсуле
CA2637275C (fr) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Composition pharmaceutique comprenant un compose bicyclique et procede pour stabiliser ce compose bicyclique
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
CA2645311C (fr) 2006-03-13 2014-11-18 R-Tech Ueno, Ltd. Composition aqueuse a base de 15-ceto-prostaglandine destinee a un usage ophtalmique
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CA2639240A1 (fr) * 2008-08-29 2010-02-28 Alphora Research Inc. Synthese de prostaglandine et intermediaires associes
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2012137987A1 (fr) 2011-04-07 2012-10-11 Sucampo Ag Procédé de traitement de l'asthénopie
AU2012293157A1 (en) 2011-08-05 2014-03-13 Sucampo Ag Method for treating schizophrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
GB201418567D0 (en) * 2014-10-20 2014-12-03 Syngenta Participations Ag Improvements in or relating to organic compounds
US20170020890A1 (en) 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853951A (en) * 1971-07-14 1974-12-10 American Cyanamid Co Preparation of 9-oxo-13-trans-prostenoic acid esters by alanate addition to cyclopentenone
US4018811A (en) * 1972-02-11 1977-04-19 American Cyanamid Company 3-Alkyl-2-(6-carboxyhexyl)cyclopentanones and esters and salts thereof
CA1027118A (fr) * 1972-04-03 1978-02-28 Martin J. Weiss 3-alkyle-2-(6-carboxyhexyle) cyclopentanones, acides et esters derives
US3981868A (en) 1973-05-31 1976-09-21 American Cyanamid Company Derivatives of 9-oxo-13-trans-prostenoic acid amides
US3974195A (en) 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
US4026909A (en) 1975-07-14 1977-05-31 The Upjohn Company Cis-13-PGF2.sub.α analogs
US4166187A (en) 1977-04-11 1979-08-28 The Upjohn Company 9-deoxy-9-methylene-16-phenyl-5,6-didehydro-pgf2 or 4,4,5,5-tetradehydro-pgf1 compounds
CA2030345C (fr) * 1989-11-22 1998-12-08 Ryuji Ueno Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques
US5140271A (en) 1989-12-26 1992-08-18 Texaco Inc. Watercut means and method with debris reducing test cell
US5292754A (en) 1990-03-08 1994-03-08 Shionogi & Co., Ltd. Treatment for hypertension or glaucoma in eyes
TW224942B (fr) * 1990-04-04 1994-06-11 Adka Ueno Kk
BE1004080A6 (fr) * 1990-04-18 1992-09-22 Centre Rech Metallurgique Procede pour le controle automatique de la qualite d'un composant de carrosserie automobile.
CA2046069C (fr) * 1990-07-10 2002-04-09 Ryuji Ueno Traitement des maladies inflammatoires au moyen de composes de 15-cetoprostaglandine
JPH07113012B2 (ja) * 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.

Also Published As

Publication number Publication date
CN102126998A (zh) 2011-07-20
CA2229183C (fr) 2008-11-04
JP3187438B2 (ja) 2001-07-11
AU3047897A (en) 1998-01-07
CN102126998B (zh) 2013-06-12
PT857718E (pt) 2002-11-29
CA2229183A1 (fr) 1997-12-18
AU716176B2 (en) 2000-02-17
CN101085756A (zh) 2007-12-12
WO1997047595A1 (fr) 1997-12-18
EP0857718A4 (fr) 1999-07-28
KR19990036322A (ko) 1999-05-25
TW418188B (en) 2001-01-11
ES2182088T3 (es) 2003-03-01
ATE222237T1 (de) 2002-08-15
CN100337632C (zh) 2007-09-19
US6242485B1 (en) 2001-06-05
DE69714698D1 (de) 2002-09-19
DE69714698T2 (de) 2002-12-05
EP0857718A1 (fr) 1998-08-12
EP0857718B1 (fr) 2002-08-14
CN1198737A (zh) 1998-11-11
CN101085756B (zh) 2011-03-02
NO980553L (no) 1998-04-07
US6452039B1 (en) 2002-09-17
NO980553D0 (no) 1998-02-09

Similar Documents

Publication Publication Date Title
NO980553D0 (no) Endotelinantagonist
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
MY126559A (en) Fungicidal 2-methoxybenzophenones
ID25548A (id) Senyawa-senyawa heterosiklik spiroazabisiklik terbaru
FI954651A7 (fi) Mahdollisesti substituoidut 6,8-kinoliinit
NO996429L (no) 2-substituerte 4,5-diarylimidazoler
IT1271014B (it) 3-aril-benzofuranoni come agenti stabilizzanti
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
ES2119912T3 (es) Nuevos aminometilenpeptidos como inmunosupresores.
EP0671911A4 (fr) Derives de carboxy-peptidyle utilises comme agents anti-degeneratifs actifs.
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
HRP20010238B1 (en) 2-methyl-thieno-benzodiazepine formulation
DE69818261D1 (en) Hydroxycyclopentanone
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
EP1008345A4 (fr) Agents anti-allergiques
FI941149A7 (fi) 2,4-diamino-3-hydroksikarboksyylihapon johdannaisia
KR950700297A (ko) 5-HT3-수용체 길항제로서의 2,6-메타노-2H-퀴놀리진 유도체(2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist)
HN1997000013A (es) Compuestos 1,4 dihidropiridina
BR9408162A (pt) Derivados de ácido 2,3,5,6-tetrafluorbenzóico
BR9612409A (pt) 1,2,4,6-Tiatriazinas substituídas úteis como herbididas
IT1267343B1 (it) Composizione insetticida.
ES1025316Y (es) Ambientador mejorado.
IT1276080B1 (it) Calzatura per la marcia
HN1997003676A (es) Derivados 6,5 heterobiciclicos sustituidos.
HN1997000104A (es) Derivados 6,6 heterociclicos sustituidos.